These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9714063)

  • 1. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
    Pestell KE; Medlow CJ; Titley JC; Kelland LR; Walton MI
    Int J Cancer; 1998 Sep; 77(6):913-8. PubMed ID: 9714063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
    Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
    Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
    Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
    Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.
    Horváth V; Soucek K; Svihálková-Sindlerová L; Vondrácek J; Blanárová O; Hofmanová J; Sova P; Kozubík A
    Invest New Drugs; 2007 Oct; 25(5):435-43. PubMed ID: 17520175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
    Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
    Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
    Bhatt M; Ivan C; Xie X; Siddik ZH
    Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
    Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
    Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
    Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.
    Xie X; He G; Siddik ZH
    Mol Cancer Res; 2017 Mar; 15(3):328-339. PubMed ID: 28031409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
    Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
    Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
    Siddik ZH; Mims B; Lozano G; Thai G
    Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal heterogeneity of p53 mutations in ovarian cancer.
    Manahan KJ; Taylor DD; Gerçel-Taylor C
    Int J Oncol; 2001 Aug; 19(2):387-94. PubMed ID: 11445857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
    Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.